2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.
We recently traveled to Long Island, New York, for an OncLive® State of the Science Summit™ on Breast Cancer. At the meeting, faculty from NYU Langone’s Perlmutter Cancer Center shed light on how to balance genomic and clinical risk in hormone receptor­—positive disease, novel approaches that are pushing the envelope in HER2-positive disease, and how tumor biology is being used to personalize surgical interventions. Other topics included exciting therapies that are propelling progress in the treatment of HR-positive, HER2-negative disease and how the paradigm for triple-negative disease is evolving with the emergence of antibody-drug conjugates, PARP inhibitors, and immunotherapy.
Related Content: